SIRT5 and fatty liver disease: Furthermore, it has shown that 2,3,5,4’-tetrahydroxy-stilbene-2-O-β-d-glucoside (TSG) inhibits the progression of nonalcoholic fatty liver disease (NAFLD) by increasing the expression of SIRT5, thereby preventing oxidative injury and ameliorating mitochondrial dysfunction, attenuating hepatic steatosis [115].